| Gene symbol | PMEL | Synonyms | D12S53E, HMB-45, HMB45, ME20, ME20-M, ME20M, P1, P100, PMEL17, SI, SIL, SILV, gp100 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q13.2 | dbXrefs | |
| Description | premelanosome protein | ||||
| Gene symbol | MLANA | Synonyms | MART-1, MART1 | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9p24.1 | dbXrefs | |
| Description | melan-A | ||||
| GTO ID | GTC0084 |
| Trial ID | NCT00923195 |
| Disease | Skin Cancer | Melanoma |
| Altered gene | MART-1|gp100 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | gp100/MAGE-1 TCR-T cells |
| Co-treatment | Radiation |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines |
| Year | 2009 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 090051|09-C-0051 |
| Vector information | |||
|
|||
| Cohort1: MART-1 | |||||||||||||||||
|
|||||||||||||||||
| Cohort2: gp100 | |||||||||||||||||
|
|||||||||||||||||